Glucocorticoid (GC)

DRUG3 trials

Sponsors

InflaRx GmbH, First Affiliated Hospital of Zhejiang University, Sunnybrook Health Sciences Centre

Conditions

Diffuse Large B-Cell LymphomaGranulomatosis With Polyangiitis (GPA)Microscopic Polyangiitis (MPA)Refractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRheumatoid Arthritis (RA)

Phase 1

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet recruitingNCT07159906

First Affiliated Hospital of Zhejiang UniversityDiffuse Large B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma

Start: 2025-09-08End: 2028-08-01Target: 62Updated: 2025-09-08

Phase 2

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

CompletedNCT03895801

InflaRx GmbHGranulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

Start: 2019-04-03End: 2021-06-08Updated: 2022-08-25

Phase 4

Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

Not yet recruitingNCT07245732

Sunnybrook Health Sciences CentreRheumatoid Arthritis (RA)

Start: 2026-04-01End: 2029-07-01Target: 220Updated: 2026-03-05

Related Papers

Is There a Place for Complement Inhibition with Monoclonal Anti-C5a Antibody Vilobelimab in the Treatment of Patients with ANCA-associated Vasculitis?

touchREVIEWS in RMD2022-01-01